P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6

What is it about?

This analysis of the data from a pivotal trial examined the effect of continuing treatment in patients with Crohn's Disease that were non responders to induction treatment. The results support the posology wording in the product labelling i.e. Patients with Crohn's disease, who have not shown a response may benefit from a dose of intravenous vedolizumab at week 10. Therapy should be continued every 8 weeks from week 14 in responding patients. Therapy for patients with Crohn's disease should be discontinued if no evidence of therapeutic benefit is observed by week 14.

Featured Image

Photo by Mat Napo on Unsplash

Photo by Mat Napo on Unsplash